Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells:Opportunities for therapeutic intervention

Molecular Medicine

Volumn 17, Issue 7-8, 2011, Pages 790-798

  Fuhler, Gwenny Manel ^a   Diks, Sander Henricus ^b   Peppelenbosch, Maikel Petrus ^a   Kerr, William Garrow ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CD11B ANTIGEN; CD38 ANTIGEN; CD71 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; FOCAL ADHESION KINASE; HISTONE H1; HISTONE H2A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MYOSIN LIGHT CHAIN 2; PHOSPHOPROTEIN; PROTEOME; RAPAMYCIN; S6 KINASE; SOMATOMEDIN C RECEPTOR; SYNDECAN 1;

ANTIGEN EXPRESSION; ARTICLE; AUTOPHOSPHORYLATION; BONE MARROW CELL; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPLE MYELOMA; PHOSPHOPROTEINS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PLASMA CELLS; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79960727977     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00013     Document Type: Article

References (40)

1. Kyle RA, Rajkumar SV. (2004) Multiple myeloma. N. Engl. J. Med. 351:1860-73.
2. Klein B, et al. (2003) Survival and proliferation factors of normal and malignant plasma cells. Int. J. Hematol. 78:106-13.
3. Hwang JJ, Ghobrial IM, Anderson KC. (2006) New frontiers in the treatment of multiple myeloma. ScientificWorldJournal. 6:1475-1503.
4. Zhan F, et al. (2006) The molecular classification of multiple myeloma. Blood. 108:2020-28.
5. Wurmbach E, et al. (2002) Validated genomic approach to study differentially expressed genes in complex tissues. Neurochem. Res. 27:1027-33.
6. Tarte K, et al. (2004) The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br. J. Haematol. 125:373-82.
7. Hanahan D, Weinberg RA. (2000) The hallmarks of cancer. Cell. 100:57-70.
8. Parikh K, Peppelenbosch MP, Ritsema T. (2009) Kinome profiling using peptide arrays in eukaryotic cells. Methods Mol. Biol. 527:269-80.
9. van Baal JW, et al. (2006) Comparison of kinome profiles of Barrett's esophagus with normal squamous esophagus and normal gastric cardia. Cancer Res. 66:11605-12.
10. de Borst MH, et al. (2006) Profiling of the renal kinome: A novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage. Am. J. Physiol. Renal. Physiol. 293:F428-37.
11. Lowenberg M, et al. (2006) Kinome analysis reveals nongenomic glucocorticoid receptordependent inhibition of insulin signaling. Endocrinology. 147:3555-62.
12. Lin P, Owens R, Tricot G, Wilson CS. (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121:482-88.
13. Sprynski AC, et al. (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 113:4614-26.
14. Menu E, Van VE, Van CB, Vanderkerken K. (2009) The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch. Physiol. Biochem. 115:49-57.
15. Lust JA, et al. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84:114-22.
16. Xiong Y, et al. (2006) Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J. Interferon. Cytokine Res. 26:83-95.
17. Bomsztyk K, et al. (1991) Evidence that interleukin-1 and phorbol esters activate NF-kappa B by different pathways: role of protein kinase C. Cell. Regul. 2:329-35.
18. Tseng WP, Su CM, Tang CH. (2010) FAK activation is required for TNF-alpha-induced IL-6 production in myoblasts. J. Cell. Physiol. 223:389-96.
19. Saijo K, et al. (2003) Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat. Immunol. 4:274-79.
20. Descamps G, et al. (2004) The magnitude of Akt/phosphatidylinositol 3'-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J. Immunol. 173:4953-59.
21. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W. (2003) Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene. 22:6289-95.
22. Chang H, et al. (2006) Analysis of PTEN deletions and mutations in multiple myeloma. Leuk. Res. 30:262-65.
23. Wang X, Robinson PJ. (1997) Cyclic GMPdependent protein kinase and cellular signaling in the nervous system. J. Neurochem. 68:443-56.
24. Eleutherakis-Papaiakovou V, Karali M, Kokkonouzis I, Tiliakos I, Dimopoulos MA. (2003) Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. Leuk. Lymphoma. 44:937-48.
25. Doronzo G, et al. (2004) Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur. J. Clin. Invest. 34:664-73.
26. Pour L, et al. (2009) Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann. Hematol. 89:385-9.
27. Mendes RV, Martins AR, de NG, Murad F, Soares FA. (2001) Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin's lymphomas and multiple myeloma. Histopathology. 39:172-8.
28. Kuku I, et al. (2005) Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell. Biochem. Funct. 23:47-50.
29. Uneda S, et al. (2003) A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br. J. Haematol. 120:396-404.
30. Kolb JP. (2000) Mechanisms involved in the proand anti-apoptotic role of NO in human leukemia. Leukemia. 14:1685-94.
31. Richardson PG, Mitsiades C, Ghobrial I, Anderson K. (2006) Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr. Opin. Oncol. 18:598-608.
32. Min CK, et al. (2007) Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. Jpn. J. Clin. Oncol. 37:961-8.
33. Curran MP, McKeage K. (2009) Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 69:859-88.
34. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. (2008) Alkylating agents induce activation of NFkappaB in multiple myeloma cells. Leuk. Res. 32:1144-7.
35. Chauhan D, et al. (1997) Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 15:837-43.
36. Stromberg T, et al. (2004) Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 103:3138-47.
37. Yan H, et al. (2006) Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 66:2305-13.
38. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp. Cell Res. 315:485-97.
39. Dancey JE, Curiel R, Purvis J. (2009) Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin. Oncol. 36(Suppl 3):S46-58.
40. Adjei AA, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, smallmolecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26:2139-46.